Table 3 Individual clinical outcomes
Patient | Best response (RECIST) | Time to progression (days) | First site of progression | Salvage therapy | Time to death (days) |
|---|---|---|---|---|---|
1 | SD | 189 | Local + distant | None | 254 |
2 | PR | 317 | Local | Capecitabine (maintenance); Radiation | 440 |
5 | SD | 470 | Distant | None | 490 |
6 | SD | 228 | Distant | FOLFOX | 397 |
7 | SD | 176 | Distant | Erlotinib with gemcitabine | 382 |
8 | PR | 450 | Local | None | 462 |
9 | SD | 251 | Distant | Capecitabine, FOLFOX+ABT888 | 618 |
10 | PD | 66 | Local | None | 135 |
13 | SD | 168 | Distant | None | 257 |
14 | SD | 121 | Distant | Progressed on gemcitabine, switched to lapatinib + capecitabine | 305 |